Unknown

Dataset Information

FAT1: a potential target for monoclonal antibody therapy in colon cancer.


ABSTRACT:

Background

Colorectal cancer (CRC) is one of the major causes of cancer-associated mortality worldwide. The currently approved therapeutic agents have limited efficacy.

Methods

The atypical cadherin FAT1 was discovered as a novel CRC-associated protein by using a monoclonal antibody (mAb198.3). FAT1 expression was assessed in CRC cells by immunohistochemistry (IHC), immunoblots, flow cytometry and confocal microscopy. In addition, in vitro and in vivo tumour models were done to assess FAT1 potential value for therapeutic applications.

Results

The study shows that FAT1 is broadly expressed in primary and metastatic CRC stages and detected by mAb198.3, regardless of KRAS and BRAF mutations. FAT1 mainly accumulates at the plasma membrane of cancer cells, whereas it is on

SUBMITTER: Pileri P 

PROVIDER: S-EPMC4931367 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature